Crohn’s & Colitis Congress™

Sessions Speakers Exhibitors Floor Plan Buzz
Search

Sessions (42)

1 - EFFECTIVENESS OF ORAL IRON SUPPLEMENTATION IN THE TREATMENT OF ANEMIA ASSOCIATED WITH PEDIATRIC ULCERATIVE COLITIS FLARE (Room Bristlecone 4)

18 Jan 18
2:30 PM - 2:40 PM

Tracks: Cutting-Edge Pediatric IBD, Defining Optimal Treatment Algorithms

Speaker(s): Paul Rufo MD, MMSc
Introduction: Iron deficiency anemia (IDA) is the most prevalent extra-intestinal sequelae of pediatric inflammatory bowel disease. As IV iron ther... More...

Cutting-Edge Pediatric IBD ($$) (Room Bristlecone 4)

18 Jan 18
1:00 PM - 5:00 PM

Tracks: Cutting-Edge Pediatric IBD, Pre-Congress Workshops

Speaker(s): KT Park MD, MS ; Michael Kappelman MD, MPH ; Neera Gupta MD, MAS
Member Registration Rate: $50 | Non-Member Registration Rate: $100 This inaugural pre-congress workshop is targeted to all providers who ca... More...

8 - TELEMEDICINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TELE-IBD) DECREASES INFLAMMATORY BOWEL DISEASE (IBD)-RELATED HOSPITALIZATIONS (Room Pinyon 3)

18 Jan 18
3:20 PM - 3:35 PM

Tracks: Defining Optimal Treatment Algorithms, Lloyd Mayer, MD, Young IBD Investigators Workshop

Speaker(s): Barathi Sivasailam
Background: IBD affects 1.6 million people in the US and is associated with increased healthcare utilization. Telemedicine is an alternative health... More...

The Lloyd Mayer, MD, Young IBD Investigators Clinical, Basic and Translational Research Workshop (Room Pinyon 3)

18 Jan 18
1:00 PM - 5:00 PM

Tracks: Lloyd Mayer, MD, Young IBD Investigators Workshop, Pre-Congress Workshops

Speaker(s): Benjamin Cohen ; Christina Ha MD ; Florian Rieder MD ; Karen Chachu MD, PhD
Member Registration Rate: $0 | Non-Member Registration Rate: $0 Back by popular demand for its fourth year, this half-day pre-congress work... More...

9 - INFECTIOUS AND THROMBOTIC RISKS OF PARENTERAL NUTRITION IN HOSPITALIZED PEDIATRIC IBD PATIENTS (Room Pinyon 3)

18 Jan 18
3:35 PM - 3:50 PM

Tracks: Defining Optimal Treatment Algorithms, Lloyd Mayer, MD, Young IBD Investigators Workshop

Speaker(s): Michael Kappelman MD, MPH
Background: Among hospitalized pediatric inflammatory bowel disease (IBD) patients, the decision to initiate parenteral nutrition (PN) involves bal... More...

Poster Reception (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Poster Session

More...

13 - REFINED POPULATION PHARMACOKINETIC MODEL FOR INFLIXIMAB PRECISION DOSING IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (Room Pinyon 4/5)

19 Jan 18
2:20 PM - 2:30 PM

Tracks: Defining Optimal Treatment Algorithms, Session II

Speaker(s): Laura Bauman
Background: Standard weight-based infliximab (IFX) dosing for inflammatory bowel disease (IBD) results in long-term clinical remission in only 40-6... More...

14 - POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION (Room Pinyon 4/5)

19 Jan 18
2:50 PM - 3:00 PM

Tracks: Defining Optimal Treatment Algorithms, Session II

Speaker(s): Bruce Sands MD, MS, AGAF
Background: Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor that is being investigated for IBD. In a recent trial of Crohn&rsqu... More...

P132 - A DEEPER LOOK INTO MEDICAL FOODS: WHERE IS THE BEST PATIENT-CENTERED INFORMATION? (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Najwan Alsulaimi
Background An assortment of medical foods, formulated to be consumed or administered enterally under the supervision of a physician, have establish... More...

P133 - AN ANALYSIS OF SURGICAL OUTCOMES IN IBD PATIENTS TREATED WITH AND WITHOUT BIOLOGIC THERAPY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Vineet Gudsoorkar
Background: Treatment options for inflammatory bowel disease (IBD) have expended tremendously in the past two decades. Biologics have now been incr... More...

P134 - BEYOND THE “BIG PICTURE”: CAN MICRONUTRIENTS IMPACT SURGICAL OUTCOMES IN IBD? (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Vineet Gudsoorkar
Background: Approximately 1/3rd of the patients with ulcerative colitis (UC) and 70% of those with Crohn’s disease (CD) undergo surgery over ... More...

P135 - BIOLOGICAL EVIDENCE OF TOFACITINIB EFFICACY IN CROHN'S DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Efi Kokkotou
Background: While phase II-III trials clearly demonstrated efficacy of tofacitinib, an oral small molecule pan-JAK inhibitor, in patients with UC, ... More...

P136 - CERTOLIZUMAB PEGOL IS EFFECTIVE IN THE MAINTENANCE OF RESPONSE IN MODERATE-SEVERE ULCERATIVE COLITIS: AN OPEN-LABEL MAINTENANCE STUDY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Scott Lee
Background: Tumor necrosis factor inhibitors (TNFi) are effective treatments for ulcerative colitis (UC). The TNFi certolizumab pegol (CZP) is effe... More...

P137 - CLINICAL FACTORS RELATED TO LOW BONE MINERAL DENSITY IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Hyun Seok Lee
Introduction Many factors about low bone mineral density (BMD) in patients with inflammatory bowel disease (IBD) have been reported. Background How... More...

P138 - COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB VS. INFLIXIMAB INDUCTION THERAPY IN ULCERATIVE COLITIS: EXPERIENCE OF A REAL-WORLD COHORT AT A TERTIARY IBD CENTER (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Krishna Venkata
Background: Vedolizumab (VDZ) and infliximab (IFX) are both approved as first line induction agents in moderately to severely active UC. However, t... More...

P139 - CORRELATION OF CLINICAL REMISSION WITH MUCOSAL HEALING IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Denise Young
Background: IBD therapeutic endpoints have evolved over time with the addition of mucosal healing (MH) as a treatment goal. Adult data suggest pati... More...

P140 - CURRENT STATUS OF HOME INFUSIONS FOR INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Bharati Kochar
Background: Infliximab and vedolizumab infusions pose a burden to inflammatory bowel disease (IBD) patients due to the need to travel and take time... More...

P141 - DEVELOPMENT OF A SELF-SCREENING TOOL FOR PERIANAL DISEASE IN PATIENTS WITH CROHN’S DISEASE: A PILOT STUDY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Eun Soo Kim
Backgrounds: Perianal disease including perianal fistula and perianal abscess is known as one of the poor prognostic factors of Crohn’s disea... More...

P142 - DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL TO EVALUATE INDUCTION OF CLINICAL RESPONSE IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE TREATED WITH RIFAXIMIN (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Scott Lee
Background: Antibiotics have been used to treat luminal Crohn’s disease (CD) with variable success. Rifaximin has a favorable safety profile ... More...

P143 - EARLY VERSUS DELAYED INITIATION OF POSTOPERATIVE PHARMACOLOGICAL PROPHYLAXIS TO PREVENT SURGICAL RECURRENCE AFTER INTESTINAL RESECTION IN PATIENTS WITH CROHN’S DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Zhen Guo
Background: Rates of surgical recurrence after curative intestinal resection for Crohn’s disease are high. It is unclear whether early initia... More...

P144 - ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF THERAPY TO ADALIMUMAB, INFIXIMAB OR OTHER ANTI-TNF COMPARED WITH SWITCHING FROM ANTI-TNF THERAPY TO VEDOLIZUMAB (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Michael Chiorean
Background Treatments for Crohn’s disease (CD) or ulcerative colitis (UC) include anti-TNFs and novel therapies, but optimal real-world treat... More...

P145 - GOLIMUMAB DRUG LEVELS DURING MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Pramoda Koduru
Background Therapeutic drug monitoring (TDM) has emerged as a means to optimize biologics and guide clinical decisions in inflammatory bowel diseas... More...

P146 - IMPACT OF CT-DERIVED BONE STRENGTH ASSESSMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDERGOING CT ENTEROGRAPHY IN CLINICAL PRACTICE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Francisco Maldnoado
Background: As inflammatory bowel disease (IBD) patients are at risk for low bone mineral density (BMD), we sought to evaluate: 1) the utility of b... More...

P147 - IMPLEMENTATION OF A NEW ORAL CONTRAST AGENT FOR CT AND MR ENTEROGRAPHY IN PEDIATRIC IBD CLINICAL PRACTICE: IMPACT ON TOLERABILITY, DISTENSION, IMAGE QUALITY AND DIAGNOSTIC CONFIDENCE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Leonard Haas
BACKGROUND: To evaluate the ability of pediatric patients with suspected IBD to ingest a new oral contrast agent at CT or MR enterography (CTE/MRE)... More...

P148 - LACK OF INFLUENCE OF ELDERLY AGE AND GENDER ON THE SAFETY PROFILE OF BUDESONIDE EXTENDED-RELEASE TABLETS FOR ULCERATIVE COLITIS: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIALS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Gary Lichtenstein
Background: Budesonide extended-release tablets (multimatrix [MMX]) are indicated for induction of remission of mild to moderate ulcerative colitis... More...

P149 - LONG-TERM SAFETY AND EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A TERTIARY CARE CENTER'S EXPERIENCE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Obada Tabbaa
Introduction Fecal Microbiota Transplantation (FMT) is an effective and safe therapy for antibiotic-resistant Clostridium Difficile Infection (CDI)... More...

P150 - MICROBIOME RISK SCORE (MRS) IN THE DIAGNOSIS AND CLASSIFICATION OF INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Khuong Le
Inflammatory bowel disease (IBD) is a common, complex and chronic condition of the GI tract. Crohn’s disease (CD) and ulcerative colitis (UC)... More...

P151 - NONIMMUNITY AGAINST HEPATITIS B VIRUS IN PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Hyun Seok Lee
Introduction Currently, there are no data on the prevalence rate of hepatitis B virus (HBV) serologic markers in patients with newly diagnosed infl... More...

P152 - PATIENT EXPERIENCES WITH COLORECTAL CANCER SURVEILLANCE (CRC) IN INFLAMMATORY BOWEL DISEASE (IBD): A QUALITATIVE STUDY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Jason Hou
Background: Understanding how IBD patients’ experiences with colonoscopy influence their acceptance and participation in CRC surveillance col... More...

P153 - PATIENT, PARENT, AND PROVIDER PERCEPTIONS OF BARRIERS TO PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Jennifer Dotson
Background: Children with inflammatory bowel disease (IBD) have a significant life-long burden as a result of disease, impacted by environmental an... More...

P154 - PRIMARY NON-RESPONSE TO TUMOR NECROSIS FACTOR ANTAGONISTS IS ASSOCIATED WITH INFERIOR RESPONSE TO SECOND-LINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Siddharth Singh
Background and Aims: We sought to analyze whether response to second-line biologic varies depending on reason for discontinuation of primary anti-T... More...

P155 - REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Stefan Schreiber
Background: Vedolizumab (VDZ) is used to treat Crohn’s disease (CD) and ulcerative colitis (UC). Data from large real-world (RW) cohorts can ... More...

P156 - REDUCTION IN THE PREVALENCE OF ANEMIA AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER IMPLEMENTATION OF THE ANEMIA CARE PATHWAY (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Jason Hou
Background: Anemia is a common but under-recognized complication of inflammatory bowel diseases (IBD). Anemia in IBD is associated with increased r... More...

P157 - REPLICATING THE PATIENT’S APPROACH: A SEARCH FOR MEDICAL FOODS IN IBD (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Nicole Doria
Inflammatory Bowel Disease is a group of chronic and relapsing diseases that can be associated with poor nutrient absorption. Despite the rise in b... More...

P158 - RISK FACTORS FOR NON-ADHERENCE TO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Brian Wentworth
Background: Non-adherence to medications is common in patients with inflammatory bowel disease (IBD). The aim of this study was to assess adherence... More...

P159 - SEARCHING FOR MORE: THE NEED FOR HIGH-QUALITY INFORMATION AND PATIENT-CENTERED LANGUAGE IN ONLINE RESOURCES FOR MEDICAL FOODS IN IBD (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Marie Borum
Patients hoping to improve their understanding of treatments recommended by their providers frequently turn to the Internet as their source of info... More...

P160 - SERUM ALBUMIN WEEK 6/WEEK 0 RATIO AFTER anti-TNF BEST PREDICTS BOTH SHORT- AND LONG-TERM CLINICAL OUTCOMES IN ANTI-TNF-NAÏVE ULCERATIVE COLITIS PATIENTS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Sun-Ho Lee
Background: The aim of this study was to investigate the predictors of short- and long-term clinical response to the initial anti-TNFs in moderate ... More...

P161 - SUSTAINABLE IMPROVEMENTS IN URGENT CARE ACCESS AND OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH IMPLEMENTATION OF AN URGENT ACCESS TOOLKIT. (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Jason Hou
Background: Patients with inflammatory bowel disease (IBD) without adequate access to urgent medical care for exacerbation of symptoms tend to obta... More...

P162 - THE GENE EXPRESSION LANDSCAPE OF COBBLESTONE LESIONS IN CROHN’S DISEASE-LIKE ILEITIS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Alex Rodriguez-Palacios
Background: We recently described cobblestone (Cob) lesions in the ileum of SAMP1/YitFc (SAMP) mice, which is the only inbred mouse strain with pol... More...

P163 - TRANSITION TO BIOLOGIC HOME INFUSIONS IN IBD PATIENTS IS ASSOCIATED WITH HIGH DROP OUT WITHIN ONE YEAR (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Marc Fenster
Introduction: Optimal inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous (IV) infusion. Until re... More...

P164 - USING EXOME SEQUENCING TO EXPAND THE GENETIC ARCHITECTURE OF INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Dermot McGovern
Background: IBD studies over the past decade have confirmed association to 250 gene loci. A handful of associations have led to specific validated ... More...

P165 - UTILIZATION OF REACTIVE DRUG LEVEL MONITORING IN INFLAMMATORY BOWEL DISEASE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): George Christophi
Background: Biologics and thiopurines are standard therapies in the management of Crohn’s disease (CD) and ulcerative colitis (UC). Reactive ... More...

P166 - VEDOLIZUMAB MARKET ACCESS ANALYSIS OF HEALTH INSURANCE IBD POLICIES (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Parambir Dulai
Background: Although traditional treatment algorithms for Crohn's disease (CD) and ulcerative colitis (UC) are based on stepwise drug failure, ... More...

P167 - VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Badr Al Bawardy
Background/Aims: The utility of vedolizumab (VDZ) trough levels (VTL) in the management of patients with inflammatory bowel disease (IBD) has not b... More...

P168 - WHERE WILL FECAL MICROBIOTA TRANSPLANTATION FIT IN THE TREATMENT ALGORITHMS FOR CROHN’S DISEASE AND ULCERATIVE COLITIS: A SYNTHESIS OF COMPLETED, ONGOING AND FUTURE TRIALS (Room Poster Hall)

19 Jan 18
5:30 PM - 7:00 PM

Tracks: Defining Optimal Treatment Algorithms

Speaker(s): Yiran Song
Background The United States Food and Drug Administration (FDA) exercises enforcement discretion for fecal microbiota transplantation (FMT) for Clo... More...